It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics ...

Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an ...

A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance ...

Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically ...

Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell ...

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

Formerly known as Verge Genomics, the new Verge Labs will help pharma and biotech partners match potential brain drugs to ...

Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, ...

Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an ...

Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 ...

Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for ...

Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.